CY1119918T1 - Συνθεσεις γαμμα-υδροξυβουτυρικου και η χρηση τους για την αντιμετωπιση διαταραχων - Google Patents

Συνθεσεις γαμμα-υδροξυβουτυρικου και η χρηση τους για την αντιμετωπιση διαταραχων

Info

Publication number
CY1119918T1
CY1119918T1 CY20181100181T CY181100181T CY1119918T1 CY 1119918 T1 CY1119918 T1 CY 1119918T1 CY 20181100181 T CY20181100181 T CY 20181100181T CY 181100181 T CY181100181 T CY 181100181T CY 1119918 T1 CY1119918 T1 CY 1119918T1
Authority
CY
Cyprus
Prior art keywords
disorders
treatment
gamma
hydroxybutyrate
dyspnea
Prior art date
Application number
CY20181100181T
Other languages
Greek (el)
English (en)
Inventor
Clark P. Allphin
Michael Desjardin
Original Assignee
Jazz Pharmaceuticals Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49596603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119918(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Ireland Limited filed Critical Jazz Pharmaceuticals Ireland Limited
Publication of CY1119918T1 publication Critical patent/CY1119918T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CY20181100181T 2012-12-14 2018-02-14 Συνθεσεις γαμμα-υδροξυβουτυρικου και η χρηση τους για την αντιμετωπιση διαταραχων CY1119918T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737695P 2012-12-14 2012-12-14
PCT/US2013/074954 WO2014093791A1 (en) 2012-12-14 2013-12-13 Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Publications (1)

Publication Number Publication Date
CY1119918T1 true CY1119918T1 (el) 2018-06-27

Family

ID=49596603

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100181T CY1119918T1 (el) 2012-12-14 2018-02-14 Συνθεσεις γαμμα-υδροξυβουτυρικου και η χρηση τους για την αντιμετωπιση διαταραχων
CY20201101030T CY1123498T1 (el) 2012-12-14 2020-11-02 Συνθεσεις γαμμα-υδροξυβουτυρικου και η χρηση τους για την αντιμετωπιση διαταραχων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201101030T CY1123498T1 (el) 2012-12-14 2020-11-02 Συνθεσεις γαμμα-υδροξυβουτυρικου και η χρηση τους για την αντιμετωπιση διαταραχων

Country Status (24)

Country Link
US (9) US8591922B1 (cg-RX-API-DMAC7.html)
EP (3) EP2931268B1 (cg-RX-API-DMAC7.html)
JP (1) JP6215347B2 (cg-RX-API-DMAC7.html)
KR (1) KR102180343B1 (cg-RX-API-DMAC7.html)
CN (1) CN105025892B (cg-RX-API-DMAC7.html)
AU (1) AU2013359114B2 (cg-RX-API-DMAC7.html)
CA (1) CA2894876C (cg-RX-API-DMAC7.html)
CY (2) CY1119918T1 (cg-RX-API-DMAC7.html)
DK (2) DK3335709T3 (cg-RX-API-DMAC7.html)
ES (2) ES2660056T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201685T1 (cg-RX-API-DMAC7.html)
HU (1) HUE051060T2 (cg-RX-API-DMAC7.html)
IL (1) IL239355A (cg-RX-API-DMAC7.html)
IN (1) IN342829B (cg-RX-API-DMAC7.html)
LT (1) LT3335709T (cg-RX-API-DMAC7.html)
MX (1) MX366681B (cg-RX-API-DMAC7.html)
NO (1) NO3027826T3 (cg-RX-API-DMAC7.html)
PL (1) PL2931268T3 (cg-RX-API-DMAC7.html)
PT (2) PT3335709T (cg-RX-API-DMAC7.html)
SG (1) SG11201504637TA (cg-RX-API-DMAC7.html)
SI (1) SI3335709T1 (cg-RX-API-DMAC7.html)
TR (1) TR201802271T4 (cg-RX-API-DMAC7.html)
TW (2) TWI681770B (cg-RX-API-DMAC7.html)
WO (1) WO2014093791A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012024019B1 (pt) 2010-03-24 2021-10-19 Jazz Phamaceuticals, Inc Forma de dosagem de liberação controlada para administração oral
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
CA3207643A1 (en) 2015-09-23 2017-03-30 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
FR3049463B1 (fr) 2016-04-01 2019-07-05 Debregeas Et Associes Pharma Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) * 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
IL275444B2 (en) 2017-12-18 2025-01-01 Tris Pharma Inc Modified release drug powder formulation containing gastric-retaining raft-forming systems with pulsed drug release
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
US11666546B2 (en) 2017-12-18 2023-06-06 Tris Pharma, Inc GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11400052B2 (en) 2018-11-19 2022-08-02 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
AU2020231916B2 (en) 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US20210186907A1 (en) * 2019-12-24 2021-06-24 Jazz Pharmaceuticals Ireland Limited Ghb dosing
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
KR102436227B1 (ko) * 2020-05-29 2022-08-24 주식회사 케이티앤지 기능성 물질이 코팅된 흡연물품용 팁페이퍼 및 상기 팁페이퍼의 코팅 방법
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) * 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
AU2021357705B2 (en) 2020-10-05 2024-09-26 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
US20230404950A1 (en) 2020-10-08 2023-12-21 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
TW202228666A (zh) 2020-10-16 2022-08-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 使用ghb之治療方法
EP4308086B1 (en) 2021-03-19 2025-10-15 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
CA3209150A1 (en) * 2021-03-20 2022-09-29 Jayprakash Ajitsingh PARIHAR A process for the preparation of mixed oxybate salts and polymorphs thereof
US11877992B1 (en) 2021-06-07 2024-01-23 Kelly Kathleen Spinelli Gamma-hydroxybutyrate salts for the treatment of learning disorders
US11877993B1 (en) 2021-06-23 2024-01-23 Kelly Kathleen Spinelli Gamma-hydroxybutyrate salts for the treatment of psychological disorders
WO2023062018A1 (en) 2021-10-11 2023-04-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
WO2023135150A1 (en) 2022-01-11 2023-07-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
CN118974001A (zh) 2022-04-21 2024-11-15 泽夫拉治疗公司 γ-羟基丁酸酯递送化合物以及制备和使用它们的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB922029A (en) 1960-05-19 1963-03-27 Equilibre Biolog L Therapeutic composition
US4374441A (en) 1980-05-23 1983-02-22 Book Covers, Inc. Method of making a book cover and pocket element therefor
EP0044801B1 (de) 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel
ZA814854B (en) 1980-07-17 1982-07-28 J Klosa Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts
EP0235408B1 (en) 1984-08-06 1991-01-09 The University Of Toronto Innovations Foundation Pharmaceutical composition and treatment
US4738985A (en) 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
IT1217783B (it) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
JP2564690B2 (ja) 1990-06-14 1996-12-18 三省製薬 株式会社 メラニン生成抑制外用剤
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
IT1271403B (it) 1993-03-26 1997-05-28 Ct Lab Farm Srl Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi
IT1266565B1 (it) 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5840331A (en) 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin
IT1283782B1 (it) 1996-08-09 1998-04-30 Ct Lab Farm Srl Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
US6495598B1 (en) 1997-04-22 2002-12-17 Ophtecs Corporation Perfusate preparation for ophthalmic operation
US5990162A (en) 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
ATE238783T1 (de) 1998-12-23 2003-05-15 Orphan Medical Inc Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten
CA2423358C (en) 2000-09-22 2011-05-17 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
FR2817256B1 (fr) 2000-11-27 2005-07-15 Univ Pasteur Derives de l'acides 4-hydroxybutanoique et de son homologue superieur comme ligands des recepteurs du gamma- hydroxybutyrate (ghb), compositions pharmaceutiques les contenant et utilisations pharmaceutiques
WO2006124609A2 (en) * 2005-05-16 2006-11-23 Joseph Johnson Methods and compositions for treating arg
US8778398B2 (en) * 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8410304B2 (en) 2009-04-15 2013-04-02 Norac Pharma Process for preparing gamma-hydroxybutyrate
MX340591B (es) * 2010-05-04 2016-07-15 Jazz Pharmaceuticals Inc * Formulaciones de liberacion inmediata y formas de dosis de gamma-hidroxibutirato.
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Also Published As

Publication number Publication date
NO3027826T3 (cg-RX-API-DMAC7.html) 2017-12-16
IL239355A0 (en) 2015-07-30
US20140171505A1 (en) 2014-06-19
CA2894876C (en) 2017-08-29
US20140171506A1 (en) 2014-06-19
EP3799867A1 (en) 2021-04-07
US20200338029A1 (en) 2020-10-29
TWI639425B (zh) 2018-11-01
IL239355A (en) 2017-05-29
KR20150100737A (ko) 2015-09-02
SG11201504637TA (en) 2015-07-30
MX2015007531A (es) 2016-03-11
PT2931268T (pt) 2018-02-27
LT3335709T (lt) 2020-11-25
HUE051060T2 (hu) 2021-03-01
EP2931268A4 (en) 2016-06-01
US9555017B2 (en) 2017-01-31
AU2013359114A1 (en) 2015-07-02
DK3335709T3 (da) 2020-10-19
PT3335709T (pt) 2020-10-21
TW201831174A (zh) 2018-09-01
MX366681B (es) 2019-07-19
EP3335709A1 (en) 2018-06-20
IN342829B (cg-RX-API-DMAC7.html) 2016-07-01
US8901173B2 (en) 2014-12-02
US20220000815A1 (en) 2022-01-06
TR201802271T4 (tr) 2018-03-21
AU2013359114B2 (en) 2017-01-19
CA2894876A1 (en) 2014-06-19
US20170209396A1 (en) 2017-07-27
US9132107B2 (en) 2015-09-15
EP2931268B1 (en) 2017-11-22
JP2016503762A (ja) 2016-02-08
ES2660056T3 (es) 2018-03-20
CY1123498T1 (el) 2022-03-24
KR102180343B1 (ko) 2020-11-19
CN105025892A (zh) 2015-11-04
DK2931268T3 (en) 2018-02-26
WO2014093791A1 (en) 2014-06-19
TW201429469A (zh) 2014-08-01
US8591922B1 (en) 2013-11-26
ES2827005T3 (es) 2021-05-19
US11554102B2 (en) 2023-01-17
JP6215347B2 (ja) 2017-10-18
EP3335709B1 (en) 2020-08-12
US10675258B2 (en) 2020-06-09
US10195168B2 (en) 2019-02-05
HK1215181A1 (en) 2016-08-19
CN105025892B (zh) 2018-03-20
PL2931268T3 (pl) 2018-06-29
US20190224149A1 (en) 2019-07-25
TWI681770B (zh) 2020-01-11
EP2931268A1 (en) 2015-10-21
US20160058720A1 (en) 2016-03-03
US20240156759A1 (en) 2024-05-16
HRP20201685T1 (hr) 2020-12-25
BR112015014007A2 (pt) 2017-07-11
SI3335709T1 (sl) 2021-01-29

Similar Documents

Publication Publication Date Title
CY1119918T1 (el) Συνθεσεις γαμμα-υδροξυβουτυρικου και η χρηση τους για την αντιμετωπιση διαταραχων
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
UA109010C2 (en) Morpholino pyrividines and their use in therapy
EA201491486A1 (ru) Производные пиперидинопиримидина для лечения вирусных инфекций
EA201391285A1 (ru) Производные тетрагидрохинолина, полезные в качестве ингибиторов бромодомена
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
UA114476C2 (uk) Хіназолінові похідні для лікування вірусних інфекцій та подальших захворювань
EA201370018A1 (ru) Составы рифаксимина и их применение
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
IL239022B (en) Tetracycline topical formulations, preparation and uses thereof
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
CL2014003232A1 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas.
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
EA201290590A1 (ru) Модифицированные туберкулезные антигены
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
LT2013015A (lt) Farmacinės kompozicijos
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений